Inventor · disambiguated record
Mark A. Morris
Also filed as: MORRIS MARK · MORRIS MARK A · MORRIS MARK ANTHONY
36 granted patents·19 pending applications·260 citations·filing 2003–2023
97Inventor score
Top patents by PatentIndex Score
55 records- 0198US9376448B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2013·Granted Jun 28, 2016·46 cites·10 claims
- 0297US9925188B2DNA-PK inhibitors and uses thereofVERTEX PHARMA·Filed 2016·Granted Mar 27, 2018·24 cites·18 claims
- 0396US9592232B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2014·Granted Mar 14, 2017·24 cites·13 claims
- 0495US9359380B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2014·Granted Jun 7, 2016·19 cites·25 claims
- 0595US9340557B2Substituted quinoxaline DNA-PK inhibitorsVERTEX PHARMA·Filed 2014·Granted May 17, 2016·19 cites·26 claims
- 0695US9296701B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2013·Granted Mar 29, 2016·21 cites·17 claims
- 0794US9878993B2DNA-PK inhibitors for treatment of cancerVERTEX PHARMA·Filed 2016·Granted Jan 30, 2018·10 cites·7 claims
- 0893US10786512B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2019·Granted Sep 29, 2020·3 cites·8 claims
- 0992US10973830B2Substituted quinoxaline DNA-PK inhibitorsVERTEX PHARMA·Filed 2019·Granted Apr 13, 2021·3 cites·23 claims
- 1092US10076521B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2017·Granted Sep 18, 2018·7 cites·21 claims
- 1191US10501439B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2018·Granted Dec 10, 2019·5 cites·18 claims
- 1291US10442791B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2018·Granted Oct 15, 2019·5 cites·13 claims
- 1391US10391095B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2018·Granted Aug 27, 2019·5 cites·9 claims
- 1490US9987284B2Substituted benzooxadiazole DNA-PK inhibitorsVERTEX PHARMA·Filed 2016·Granted Jun 5, 2018·5 cites·23 claims
- 1589US12043616B2Crystalline forms of nicotinamide riboside chlorideELYSIUM HEALTH INC·Filed 2022·Granted Jul 23, 2024·2 cites·20 claims
- 1689US10258627B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2017·Granted Apr 16, 2019·4 cites·19 claims
- 1787US7179822B2Hetero biaryl derivatives as matrix metalloproteinase inhibitorsWARNER LAMBERT CO·Filed 2003·Granted Feb 20, 2007·23 cites·14 claims
- 1886US12251387B2Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitorsVERTEX PHARMA·Filed 2023·Granted Mar 18, 2025·0 cites·20 claims
- 1986US8354419B2Benzimidazole analogues for the treatment or prevention of flavivirus infectionsVERTEX PHARMA·Filed 2010·Granted Jan 15, 2013·10 cites·23 claims
- 2082US11414407B2Crystalline forms of nicotinamide riboside chlorideELYSIUM HEALTH INC·Filed 2018·Granted Aug 16, 2022·2 cites·14 claims
- 2182US10183036B2Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as NAD+ increasing precursorsCHROMADEX INC·Filed 2017·Granted Jan 22, 2019·6 cites·8 claims
- 2282US8044052B2Biaryl ether urea compoundsPFIZER·Filed 2007·Granted Oct 25, 2011·8 cites·10 claims
- 2381US8779156B2Analogues for the treatment or prevention of flavivirus infectionsVERTEX PHARMA·Filed 2012·Granted Jul 15, 2014·7 cites·27 claims
- 2477US11389468B2Nicotinamide riboside for use in treating or preventing liver damageELYSIUM HEALTH INC·Filed 2018·Granted Jul 19, 2022·1 cites·10 claims
- 2577US2021236505A1Substituted quinoxaline dna-pk inhibitorsVERTEX PHARMA·Filed 2021·Application pending·0 cites
- 2676US11813267B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2020·Granted Nov 14, 2023·0 cites·19 claims
- 2776US11021465B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2019·Granted Jun 1, 2021·0 cites·22 claims
- 2875US11008305B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2019·Granted May 18, 2021·0 cites·20 claims
- 2974US12433908B2Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy developmentCHROMADEX INC·Filed 2022·Granted Oct 7, 2025·0 cites·13 claims
- 3073US11524022B2Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy developmentCHROMADEX INC·Filed 2020·Granted Dec 13, 2022·0 cites·22 claims
- 3170US12128060B2Nicotinamide riboside for use in treating or preventing liver damageELYSIUM HEALTH INC·Filed 2022·Granted Oct 29, 2024·0 cites·8 claims
- 3270US10857172B2Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy developmentCHROMADEX INC·Filed 2017·Granted Dec 8, 2020·0 cites·10 claims
- 3369US8765731B2Benzimidazole analogues for the treatment or prevention of flavivirus infectionsVERTEX PHARMA·Filed 2012·Granted Jul 1, 2014·1 cites·22 claims
- 3469US2023348521A1Methods of synthesizing nicotinamide ribosideELYSIUM HEALTH INC·Filed 2023·Application pending·0 cites
- 3569US2018311254A1Dna-pk inhibitorsVERTEX PHARMA·Filed 2018·Application pending·0 cites
- 3664US2016354381A1Dna-pk inhibitorsObligated Assignee·Filed 2016·Application pending·0 cites
- 3757US11629163B2Methods of synthesizing nicotinamide ribosideELYSIUM HEALTH INC·Filed 2018·Granted Apr 18, 2023·0 cites·5 claims
- 3857US2014243257A1Benzimidazole analogues for the treatment or prevention of flavivirus infectionsVERTEX PHARMA·Filed 2014·Application pending·0 cites
- 3956US11129843B2Treating and preventing kidney damageELYSIUM HEALTH INC·Filed 2018·Granted Sep 28, 2021·0 cites·45 claims
- 4054US2009029995A1Hetero biaryl derivatives as matrix metalloproteinase inhibitorsWARNER LAMBERT CO·Filed 2006·Application pending·0 cites
- 4153US2023339915A1Modulators of alpha-1 antitrypsinVERTEX PHARMA·Filed 2021·Application pending·0 cites
- 4248US2020261483A1Methods and compositions for treating cystic fibrosisELYSIUM HEALTH INC·Filed 2018·Application pending·0 cites
- 4347US12269804B2Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiencyVERTEX PHARMA·Filed 2019·Granted Apr 8, 2025·0 cites·8 claims
- 4447US2021177875A1Methods and compositions for treating childhood or teen obesityELYSIUM HEALTH INC·Filed 2018·Application pending·0 cites
- 4547US2021186996A1Methods and compositions for treating multiple sclerosisELYSIUM HEALTH INC·Filed 2018·Application pending·0 cites
- 4646US12005127B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2019·Granted Jun 11, 2024·0 cites·48 claims
- 4746US2021054146A1Fast preparation of low primary amine containing polyaspartic esters and use of these polyaspartic esters in slow reactivity polyurea systemsCOVESTRO LLC·Filed 2019·Application pending·0 cites
- 4845US2020085849A1Methods and compositions for improving sleepELYSIUM HEALTH INC·Filed 2018·Application pending·0 cites
- 4943US2013085150A1Analogues for the treatment or prevention of flavivirus infectionsPEREIRA OSWY Z·Filed 2012·Application pending·0 cites
- 5043US2013102629A1Analogues for the treatment or prevention of flavivirus infectionsVERTEX PHARMA·Filed 2012·Application pending·0 cites
Showing the top 50 of 55 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Mark A. Morris files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →